GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Greenyn Biotechnology Co 6846.TWO · TWD

Consumer Staples · Taipei Exchange · 🇹🇼 Taiwan

Compare

50.50

+3.06%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Greenyn Biotechnology Co

Its shares trade on Taipei Exchange under the ticker 6846.TWO. It has been listed since 19 April 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 915.3m and net income of TWD 145.5m. At that date it held total assets of TWD 2.11bn and shareholders' equity of TWD 978.6m.

Greenyn Biotechnology Co., Ltd. engages in the research, development, manufacture and sales of health food raw materials. The company is headquartered in Taichung, Taichung. The company went IPO on 2022-04-19. The firm is engaged in the operation of business through health ingredients, health formulations, and other three business segments. The firm's main products include Antrodia cinnamomea mycelia, Bitter melon extract (Insumate), 101 Phyto Fermented Drink and others. The firm mainly provides its products in Taiwan and other Asian regions.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Consumer Staples
Industry
Personal Care Products
Listed since
19 Apr 2022

Leadership

Pay as last reported

  • Jiafeng WuChairman of the Board, since 2023
  • Yanqin HuangVice President - Operations, Director
  • Bangkui XuGeneral Manager, Deputy General Manager-Sales 1st Division, Director, since 2024
  • Yuchun SongDeputy General Manager-Sales 2nd Division
  • Qiuxue ZengHead of Finance & Accounting, Corporate Governance Officer, since 2023
  • Hongchang LinDirector
  • Mr. Chao Chin HsiaoIndependent Director
  • Wei-Chieh LiaoIndependent Director
  • Ching-Wen WangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Greenyn Biotechnology Co Ltd focuses on health food raw materials in Taiwan and Asia.
  • The company's main products include Antrodia cinnamomea mycelia and Bitter melon extract.
  • Greenyn operates through health ingredients, health formulations, and other segments.

Weaknesses

  • The company's business is limited to Taiwan and other Asian regions only.
  • Greenyn Biotechnology Co Ltd has no presence in North America or Europe.
  • The firm's product range is concentrated in health food raw materials.

Opportunities

  • Expanding into North America and Europe could increase market reach.
  • Growing demand for health food raw materials in Asia presents opportunities.
  • The company can leverage its health formulations for new markets.

Threats

  • Competition from other health food manufacturers in Asia is increasing.
  • Regulatory changes in Taiwan could affect product sales.
  • Economic downturns in Asia may reduce consumer spending on health products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.